UCB (OTCMKTS:UCBJY) Stock Crosses Above 50 Day Moving Average - Should You Sell?

UCB SA (OTCMKTS:UCBJY - Get Free Report)'s share price passed above its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $86.59 and traded as high as $88.05. UCB shares last traded at $87.81, with a volume of 20,793 shares changing hands.

UCB Stock Performance

The company has a debt-to-equity ratio of 0.33, a current ratio of 1.19 and a quick ratio of 0.78. The business has a 50-day simple moving average of $86.04 and a 200-day simple moving average of $93.24.

UCB Increases Dividend

The company also recently announced a dividend, which was paid on Wednesday, May 14th. Investors of record on Tuesday, April 29th were paid a dividend of $0.4838 per share. This is a positive change from UCB's previous dividend of $0.46. The ex-dividend date was Monday, April 28th. This represents a yield of 0.62%.

UCB Company Profile

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.